Product Details
Product Name:
ALK-IN-27 |
CAS No.:
2739866-40-9 |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | ALK-IN-27 |
Description | Neladalkib (NVL-655) is a selective and brain-permeable ALK inhibitor with antitumor activity that inhibits a variety of ALK-mutant oncoproteins, and may be useful in the study of non-small cell cancers. |
In vitro | Neladalkib is a potent ALK inhibitor with antitumor activity. Neladalkib has an IC50 = 2.7 nM for Ba/F3 CLIP1-LTK cells.[1] |
Storage | keep away from moisture | Shipping with blue ice. |
Solubility Information | DMSO : 80 mg/mL(176.64 mM), Sonication is recommended.
|
Keywords | NVL 655 |
Inhibitors Related | Alectinib hydrochloride | DMH-1 | SB-431542 | RepSox | EML4-ALK kinase inhibitor 1 | Crizotinib | Vactosertib | Ceritinib | LDN-193189 2HCl | Brigatinib | A 83-01 | ALK-IN-1 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2447607-85-2
$35.00 / 1mg
-
CAS:177028-90-9
$46.00 / 1mg
-
CAS:761438-38-4
$118.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$2140.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
|
$1980.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
|
$0.00/1Box |
VIP1Y
|
Shanghai Affida new material science and technology center
|
2024-03-20 |